Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Mizuho Securities Downgrades Eagle Pharmaceuticals (EGRX) to Neutral; Stock to Plateau Post-Analyst Day
November 16, 2016 6:28 AM ESTMizuho Securities downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Buy to Neutral while maintaining a $78 price target.
Analyst Irina Koffler commented, "We expect the stock to plateau after the Analyst Day due to lighter catalyst flow, weaker Treanda/Bendeka revenues reported by partner... More
